Article
Oncology
Carla S. S. Walti, Anna B. B. Halpern, Hu Xie, Erika S. S. Kiem, E. Lisa Chung, Kelda G. G. Schonhoff, Emily M. M. Huebner, Colleen Delaney, Catherine Liu, Steven A. A. Pergam, Guang-Shing Cheng, Louise E. E. Kimball, Wendy M. M. Leisenring, Michael Boeckh, Roland B. B. Walter, Joshua A. A. Hill
Summary: Contemporary data on infections after intensive chemotherapy for acute myeloid leukemia (AML) are scarce. Patients receiving CLAG-M for newly diagnosed or relapsed/refractory AML have higher rates of moderate to severe infections, especially in the case of relapsed/refractory disease. Improved strategies for infection prevention are needed.
Article
Hematology
Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur, Musa Yilmaz, Steven Kornblau, Yesid Alvarado, Courtney D. Dinardo, Naval Daver, Nitin Jain, Naveen Pemmaraju, Nicholas Short, Sa A. Wang, Rebecca S. S. Tidwell, Rabiul Islam, Marina Konopleva, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian
Summary: The addition of venetoclax to intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome was found to be safe and effective, leading to high rates of durable MRD-negative remissions and favorable event-free survival and overall survival outcomes.
LANCET HAEMATOLOGY
(2021)
Article
Hematology
Tapan M. Kadia, Farhad Ravandi, Matteo Molica, Alex Bataller, Gautam Borthakur, Naval Daver, Elias Jabbour, Courtney D. Dinardo, Naveen Pemmaraju, Nitin Jain, Alessandra Ferrajoli, Musa Ylimaz, Prithviraj Bose, Rebecca Slack Tidwell, Kayleigh R. Marx, Caitlin R. Rausch, Rashmi Kanagal-Shamanna, Sa Wang, Rabiul Islam, Richard Champlin, Elizabeth Shpall, Marina Konopleva, Guillermo Garcia-Manero, Hagop Kantarjian
Summary: The addition of cladribine or sorafenib to standard chemotherapy has improved survival in patients with newly-diagnosed acute myeloid leukemia (AML). The combination of cladribine, idarubicin, and intermediate-dose cytarabine (CLIA) showed high rates of complete remission in AML patients, with even better results when sorafenib was added in patients with FLT3-ITD mutated AML.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Andrew H. Matthews, Alexander E. Perl, Selina M. Luger, Saar I. Gill, Catherine Lai, David L. Porter, Sarah Skuli, Ximena Jordan Bruno, Martin P. Carroll, Craig W. Freyer, Alison Carulli, Daria V. Babushok, Noelle V. Frey, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, Edward A. Stadtmauer, Alison W. Loren, Vikram R. Paralkar, Ivan P. Maillard, Keith W. Pratz
Summary: Intensive chemotherapy with cytarabine and anthracycline remains the standard therapy for fit AML patients, but the assessment of fitness remains controversial. Venetoclax and hypomethylating agent combination therapy has improved outcomes in unfit patients, but its efficacy in fit patients has not been well studied. This retrospective study compared outcomes between patients receiving 7 & 3 and ven/HMA as initial therapy, and found that intensive chemotherapy had superior overall survival, but a subset of patients had similar outcomes with ven/HMA.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Review
Oncology
Lei Deng, Changjian Zhang, Sunyang Ying, Bo Cai, Fang Zhou
Summary: The study found that mitoxantrone significantly increased complete remission rate and disease-free survival in AML patients compared to daunorubicin, suggesting that it may be a better choice as an induction chemotherapy agent for these patients.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Article
Medicine, General & Internal
Rathnamitreyee Vegunta, Ronen Harel, Amir Steinberg
Summary: Chemotherapy remains the standard treatment for AML, but the optimal dose and safety profile when combined with new therapies like gemtuzumab-ozogamicin and FLT3 inhibitors are still being studied. Limited data suggest that intensified daunorubicin combined with gemtuzumab-ozogamicin may be effective for AML treatment, but may result in a significant decrease in platelet count.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Hematology
Aarne Kolonen, Marjatta Sinisalo, Heini Huhtala, Johanna Rimpilainen, Hannele Rintala, Marja Sankelo, Elli Koivunen, Raija Silvennoinen, Riikka Raty, Tapani Ruutu, Liisa Volin, Kimmo Porkka, Esa Jantunen, Tapio Nousiainen, Taru Kuittinen, Karri Penttila, Marja Pyorala, Marjaana Saily, Pirjo Koistinen, Marjut Kauppila, Maija Itala-Remes, Hanna Ollikainen, Auvo Rauhala, Veli Kairisto, Tarja-Terttu Pelliniemi, Erkki Elonen, Finnish Leukemia Group
Summary: The AML-2003 study compared the long-term efficacy and safety of IAT and IdAraC-Ida in induction chemotherapy for AML and emphasized the importance of a treatment strategy guided by integrated genetic and clinical risk classification.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2022)
Article
Biophysics
Arnon Nagler, Myriam Labopin, Xiao-jun Huang, Didier Blaise, William Arcese, Mercedes Colorado Araujo, Gerard Socie, Edouard Forcade, Fabio Ciceri, Jonathan Canaani, Sebastian Giebel, Eolia Brissot, Jaime Sanz Caballer, Ali Bazarbachi, Ibrahim Yakoub-Agha, Mohamad Mohty
Summary: This study compared the transplantation outcomes of AML patients undergoing HaploSCT in CR1 after one or two induction chemotherapy courses. The results showed that patients achieving CR1 with two induction courses had a higher relapse incidence and inferior leukemia-free survival, overall survival, and GVHD-free, relapse-free survival compared to those achieving CR1 with one induction course.
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Yunxiang Zhang, Xiaoyang Li, Xiangqin Weng, Yang Shen, Yu Chen, Yu Zheng, Huijin Zhao, Jianhua You, Yuanfei Mao, Lining Wang, Min Wu, Yan Sheng, Jing Wu, Jiong Hu, Qiusheng Chen, Junmin Li
Summary: Individualized chemotherapy based on D5-PBCR is feasible in newly diagnosed AML patients, and the addition of HHT shows good efficacy and safety profile. Significant improvements in both OS and EFS were observed in the D5-PBCR (+) group compared to historical data.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Hui Liu, Fen Huang, Yu Zhang, Meiqing Wu, Na Xu, Zhiping Fan, Zhiqiang Sun, Xudong Li, Dongjun Lin, Yiying Xiong, Xiaodan Liu, Ren Lin, Pengcheng Shi, Jun Xu, Zhixiang Wang, Xiaofang Li, Jing Sun, Qifa Liu, Li Xuan
Summary: This study compared the efficacy and tolerability of IDA-BuCy and BuCy in auto-HSCT for IR-AML patients. The results showed no significant difference in relapse rate, overall survival, and disease-free survival between the two groups. However, the IDA-BuCy group had higher incidence of grade 3 or worse regimen-related toxicity. Therefore, caution should be taken when choosing IDA-BuCy for IR-AML patients in CR1 with auto-HSCT.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Nikhil Patkar, Chinmayee Kakirde, Anam Fatima Shaikh, Rakhi Salve, Prasanna Bhanshe, Gaurav Chatterjee, Sweta Rajpal, Swapnali Joshi, Shruti Chaudhary, Rohan Kodgule, Sitaram Ghoghale, Nilesh Deshpande, Dhanalaxmi Shetty, Syed Hasan Khizer, Hasmukh Jain, Bhausaheb Bagal, Hari Menon, Navin Khattry, Manju Sengar, Prashant Tembhare, Papagudi Subramanian, Sumeet Gujral
Summary: NGS-MRD is an effective tool for predicting relapse risk and prognosis in AML patients, particularly in those with intermediate cytogenetic risk and favorable cytogenetic risk. The kinetics of NGS-MRD clearance is crucial for patient survival. Combining NGS-MRD with FCM-MRD provides comprehensive information for better clinical management.
Article
Hematology
Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke, Georg Maschmeyer, Haifa Kathrin Al-Ali, Sebastian Schwind, Madlen Jentzsch, Michael Cross, Christoph Kahl, Hans-Heinrich Wolf, Herbert Sayer, Antje Schulze, Peter Dreger, Ute Hegenbart, Alwin Kraemer, Christian Junghanss, Lars-Olof Muegge, Detlev Haehling, Carsten Hirt, Christian Spaeth, Norma Peter, Bernhard Opitz, Axel Florschuetz, Kolja Reifenrath, Niklas Zojer, Sebastian Scholl, Wolfram Poenisch, Simone Heyn, Vladan Vucinic, Andreas Hochhaus, Carlo Aul, Aristoteles Giagounidis, Leopold Balleisen, Bernd Oldenkott, Peter Staib, Michael Kiehl, Wolfgang Schuette, Ralph Naumann, Hartmut Eimermacher, Bernd Doerken, Cristina Sauerland, Eva Lengfelder, Wolfgang Hiddemann, Bernhard Woermann, Carsten Mueller-Tidow, Hubert Serve, Christoph Schliemann, Ruediger Hehlmann, Wolfgang E. Berdel, Markus Pfirrmann, Utz Krug, Verena S. Hoffmann
Summary: A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm in non-M3 AML patients showed no significant differences in complete remission rate, event-free survival, and overall survival between the treatment group and the standard treatment group. Therefore, more intensive treatment strategies did not demonstrate clinically relevant outcome differences compared to the standard treatment.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Silvia Park, Daehun Kwag, Tong Yoon Kim, Jong Hyuk Lee, Joon Yeop Lee, Gi June Min, Sung Soo Park, Seung-Ah Yahng, Young-Woo Jeon, Seung-Hwan Shin, Jae-Ho Yoon, Sung-Eun Lee, Byung Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Hee-Je Kim
Summary: In medically fit patients with relapsed/refractory acute myeloid leukemia (R/R AML), venetoclax combined with low intensity treatment provides a comparable anti-leukemic response and survival to intensive chemotherapy (IC), while also offering better disease control and acting as a bridge to stem cell transplantation (SCT).
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2022)
Article
Oncology
Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stephane de Botton, Amer M. Zeidan, Amir T. Fathi, Hagop M. Kantarjian, John M. Bennett, Mark G. Frattini, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Maroof Hasan, Paresh Vyas, Hartmut Doehner
Summary: The study evaluated the safety and activity of enasidenib plus azacitidine in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia, showing that the combination therapy significantly improved overall response rates compared to azacitidine monotherapy, which may lead to improved outcomes for these patients.
Letter
Hematology
Frederic Baron, Fabio Efficace, Laura Cannella, Roel Willemze, Marco Vignetti, Petra Muus, Jean-Pierre Marie, Dario Ferrero, Paola Fazi, Edoardo La Sala, Jean-Henri Bourhis, Francesco Fabbiano, Alberto Bosi, Marco Sborgia, Giovanni Martinelli, Sebastian Wittnebel, Silvia Trisolini, Maria Concetta Petti, Constantijn J. M. Halkes, Walter J. F. M. van der Velden, Theo de Witte, Sergio Amadori, Robert A. Zittoun, Stefan Suciu
Letter
Oncology
Laura Cicconi, Uwe Platzbecker, Giuseppe Avvisati, Francesca Paoloni, Christian Thiede, Marco Vignetti, Paola Fazi, Felicetto Ferrara, Mariadomenica Divona, Francesco Albano, Fabio Efficace, Marco Sborgia, Eros Di Bona, Massimo Breccia, Erika Borlenghi, Roberto Cairoli, Alessandro Rambaldi, Lorella Melillo, Giorgio La Nasa, Walter Fiedler, Peter Brossart, Bernd Hertenstein, Helmut R. Salih, Ombretta Annibali, Mohammed Wattad, Michael Lubbert, Christian H. Brandts, Mathias Hanel, Christoph Rollig, Norbert Schmitz, Hartmut Link, Chiara Frairia, Claudio Fozza, Alfonso Maria D'Arco, Nicola Di Renzo, Agostino Cortelezzi, Francesco Fabbiano, Konstanze Dohner, Arnold Ganser, Hartmut Dohner, Sergio Amadori, Franco Mandelli, Maria Teresa Voso, Gerhard Ehninger, Richard F. Schlenk, Francesco Lo-Coco
Article
Hematology
Sabina Chiaretti, Monica Messina, Irene Della Starza, Alfonso Piciocchi, Luciana Cafforio, Marzia Cavalli, Akram Taherinasab, Michela Ansuinelli, Loredana Elia, Guglielmo Albertini Petroni, Roberta La Starza, Martina Canichella, Alessia Lauretti, Maria Cristina Puzzolo, Valentina Pierini, Alessandra Santoro, Orietta Spinelli, Valerio Apicella, Saveria Capria, Francesco Di Raimondo, Paolo De Fabritiis, Cristina Papayannidis, Anna Candoni, Roberto Cairoli, Marco Cerrano, Nicola Fracchiolla, Daniele Mattei, Chiara Cattaneo, Antonella Vitale, Enrico Crea, Paola Fazi, Cristina Mecucci, Alessandro Rambaldi, Anna Guarini, Renato Bassan, Robin Foa
Summary: The study revealed significant differences in treatment and outcomes for Ph-like ALL patients, including low remission rates and poorer survival rates, emphasizing the importance of early recognition of this subset of patients.
Letter
Oncology
Massimo Breccia, Alfonso Piciocchi, Valerio De Stefano, Guido Finazzi, Alessandra Iurlo, Paola Fazi, Stefano Soddu, Bruno Martino, Francesca Palandri, Sergio Siragusa, Francesco Albano, Francesco Passamonti, Marco Vignetti, Alessandro M. Vannucchi
Article
Hematology
Anna Maria Testi, Martina Canichella, Antonella Vitale, Alfonso Piciocchi, Anna Guarini, Irene Della Starza, Marzia Cavalli, Maria Stefania De Propris, Monica Messina, Loredana Elia, Maria Luisa Moleti, Bruno Martino, Mario Luppi, Marianna D'Aloisio, Anna Candoni, Valentino Conter, Paola Fazi, Marco Vignetti, Sabina Chiaretti, Roberto Foa
Summary: The study shows that a pediatric-inspired and MRD-oriented treatment protocol is feasible and effective for Ph- AYA ALL patients. Early MRD analysis during treatment can predict patients' overall survival and disease-free survival.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Review
Economics
Fabio Efficaee, Gary S. Collins, Francesco Cottone, Johannes M. Giesinger, Kathrin Sommer, Amelie Anota, Michael Maia Schlussel, Paola Fazi, Marco Vignetti
Summary: This systematic review found that PROs are statistically significant predictors of survival in cancer patients, with the EORTC QLQ-C30 questionnaire playing a particularly important role in predicting overall survival. Further research is needed to develop prognostic tools based on this evidence to assist in clinical decision-making.
Article
Hematology
Sabina Chiaretti, Michela Ansuinelli, Antonella Vitale, Loredana Elia, Mabel Matarazzo, Alfonso Piciocchi, Paola Fazi, Francesco Di Raimondo, Lidia Santoro, Francesco Fabbiano, Catello Califano, Giovanni Martinelli, Francesca Ronco, Felicetto Ferrara, Nicola Cascavilla, Catia Bigazzi, Alessandra Tedeschi, Simona Sica, Nicola Di Renzo, Angela Melpignano, Germana Beltrami, Marco Vignetti, Robin Foa
Summary: The study showed that long-term survival can be achieved in adult Philadelphia chromosome positive acute lymphoblastic leukemia patients with a total-therapy strategy based on chemotherapy-free induction and, in complete molecular responders, without further systemic chemotherapy. Patients with additional copy number aberrations exhibited worse survival outcomes, highlighting the importance of screening for these abnormalities in diagnostic work-up.
Article
Health Care Sciences & Services
Laura B. Oswald, Adriano Venditti, David Cella, Francesco Cottone, Anna Candoni, Lorella Melillo, Roberto Cairoli, Gabriella Storti, Prassede Salutari, Mario Luppi, Francesco Albano, Maria Paola Martelli, Antonio Cuneo, Agostino Tafuri, Silvia Maria Trisolini, Alessia Tieghi, Paola Fazi, Marco Vignetti, Fabio Efficace
Summary: This study found that patients newly diagnosed with AML reported more severe fatigue compared to the general population, with mean differences exceeding the clinical significance threshold. Factors associated with higher pretreatment fatigue levels included female sex, WHO performance status >= 1, and lower platelet levels.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2021)
Letter
Hematology
Alfonso Piciocchi, Monica Messina, Loredana Elia, Antonella Vitale, Stefano Soddu, Anna Maria Testi, Sabina Chiaretti, Marco Mancini, Francesco Albano, Antonio Spadano, Mauro Krampera, Massimiliano Bonifacio, Roberto Cairoli, Calogero Vetro, Florinda Colella, Felicetto Ferrara, Giuseppe Cimino, Renato Bassan, Paola Fazi, Marco Vignetti
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Hematology
Maria Cristina Puzzolo, Giulia Radice, Nadia Peragine, Maria Stefania de Propris, Paola Mariglia, Marco Vignetti, Antonella Vitale, Renato Bassan, Mario Annunziata, Gianluca Gaidano, Alessandro Rambaldi, Sabina Chiaretti, Anna Guarini, Robin Foa
Article
Oncology
Francesco Mannelli, Giacomo Gianfaldoni, Paola Guglielmelli, Francesco Buccisano, Roberto Caporale, Marco Chiarini, Giuseppe Rossi, Adriano Venditti, Paola Fazi, Enrico Crea, Alfonso Piciocchi, Maria Teresa Voso, Marco Vignetti, Sergio Amadori, Alessandro Maria Vannucchi
Summary: AMELIORATE is a Phase III trial aiming to personalize treatment intensity in FLT3-mutated acute myeloid leukemia by early intensification of treatment in patients predicted to have a poor response based on peripheral blast clearance speed.
Article
Health Care Sciences & Services
Fabio Efficace, Massimo Breccia, Paola Fazi, Francesco Cottone, Bernhard Holzner, Marco Vignetti
Summary: The GIMEMA-ALLIANCE platform aims to improve patient care for hematologic malignancies during and after the COVID-19 pandemic by collecting patient data and enabling real-time remote consultations.
JMIR RESEARCH PROTOCOLS
(2021)
Letter
Hematology
Caterina Giovanna Valentini, Alfonso Piciocchi, Fabio Facchetti, Fabio Guolo, Alessandro Pulsoni, Marco Vignetti, Livio Pagano
Article
Health Care Sciences & Services
Francesco Cottone, Gary S. Collins, Amelie Anota, Kathrin Sommer, Johannes M. Giesinger, Jacobien M. Kieffer, Neil K. Aaronson, Kristel Van Steen, Emilie Charton, Fausto Castagnetti, Paola Fazi, Marco Vignetti, David Cella, Fabio Efficace
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2020)